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ABSTRACT 26 
 27 
Virion-associated peptidoglycan hydrolases have a potential as antimicrobial agents due 28 
to their ability to lyse Gram positive bacteria on contact. In this work, our aim was to 29 
improve the lytic activity of HydH5, a virion associated peptidoglycan hydrolase from 30 
the Staphylococcus aureus bacteriophage vB_SauS-phi-IPLA88. Full-length HydH5 31 
and two truncated derivatives containing only the CHAP domain exhibited high lytic 32 
activity against live S. aureus cells. In addition, three different fusion proteins were 33 
created between lysostaphin and HydH5, each of which showed higher staphylolytic 34 
activity than the parental enzyme or its deletion construct. Both parental and fusion 35 
proteins lysed S. aureus cells in zymograms, plate lysis and turbidity reduction assays. 36 
In plate lysis assays, the HydH5 and its derivative fusions lysed bovine and human S. 37 
aureus, S. aureus MRSA N315 strain, and human Staphylococcus epidermidis strains. 38 
Several non-staphylococcal bacteria were not affected. HydH5 and its derivative fusions 39 
proteins displayed antimicrobial synergy with the endolysin LysH5 in vitro suggesting 40 
that the two enzymes have distinct cut sites and thus may be more efficient in 41 
combination for the elimination of staphylococcal infections. 42 
43 
 3
INTRODUCTION 44 
 45 
 Staphylococcus aureus is a notorious pathogen that causes numerous pathologies 46 
including food poisoning, toxic shock syndrome, endocarditis, and skin and wound 47 
infections (26). The emergence of multidrug-resistant strains, especially methicillin-48 
resistant S. aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) is raising 49 
serious concerns due to their high frequency in both nosocomial and community-50 
acquired settings (21). Antibiotic resistance in combination with other important 51 
virulence determinants, such as, surface-located binding proteins to facilitate adhesion 52 
to host tissue as well as many mechanisms to evade attack by human host defenses 53 
makes S. aureus a threatening pathogen (35) and novel therapeutic agents are sorely 54 
needed. 55 
 Bacteriophages are a feasible alternative to antibiotics for the treatment of 56 
bacterial infections (30). In addition, phage peptidoglycan (PG) hydrolases have 57 
demonstrated a valuable antimicrobial activity against Gram positive pathogens (11, 58 
16). Most PG hydrolases are modular proteins composed of a C-terminal CWB domain 59 
and N-terminal catalytic domain(s) (10). Specifically, there are three major PG 60 
hydrolase activities, namely, (i) glycosidase, (ii) amidase, and (iii) endopeptidase 61 
activities.  62 
 Recent results with phage therapy in animal models have driven much interest in 63 
phages and phage-encoded proteins to treat infections (34, 9). These studies clearly 64 
show the efficacy of phages and lysins in killing human pathogenic bacteria in animal 65 
models (30, 11). Specifically, several assays have been performed against S. aureus 66 
bacteraemia. The intraperitoneal administration of phages phiMR11 and phiMR25 67 
rescued mice inoculated with a lethal dose of S. aureus (29, 18). Moreover, in a rabbit 68 
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model of wound infection caused by S. aureus, phages prevented abscess formation 69 
(43). Phage lytic proteins also showed successful results. The intraperitoneal 70 
administration of the endolysin MV-L from phage phiMR11 protected mice against S. 71 
aureus MRSA septic death (37). In other animal models, bacteraemia in unprotected 72 
mice reached colony counts of ~107 CFU/ml within 3.5 h after challenge, whereas the 73 
administration of the lytic enzyme LysGH15 1 h after MRSA injection was sufficient to 74 
protect mice with the mean colony count being less than 104 CFU/ml (14). Furthermore, 75 
the activity of phage lytic proteins may be increased by using them in combination with 76 
other antimicrobials. Both in vitro (2, 5, 13) and in vivo synergy (5) between phage 77 
endolysin constructs and antibiotics or bacteriocins against S. aureus have been 78 
reported.  79 
 In addition to endolysins, other phage encoded proteins (virion-associated 80 
peptidoglycan hydrolases) have potential as antimicrobials. Some bacteriophages 81 
virions harbor peptidoglycan (PG) hydrolases that facilitate the entry of phage DNA 82 
across the bacterial cell envelope during infection (31). They are also responsible for the 83 
“lysis from without”, a phenomenon caused by some phages when adsorbed onto the 84 
host cell at very high numbers (6). This type of PG hydrolase lytic activity has been 85 
described from a variety of different phage particles infecting S. aureus (31, 38, 42), 86 
Lactococcus lactis (20), E. coli (32, 19), and Salmonella (41). 87 
 Recently, a PG hydrolase (HydH5) encoded by phage vB_SauS-phiIPLA88 88 
(phiIPLA88) has been identified and characterized (39). HydH5 has an N-terminal 89 
CHAP (cysteine, histidine-dependent amidohydrolase/peptidase) lytic domain and a C-90 
terminal LYZ2 (lysozyme subfamily 2) lytic domain, but it does not have a recognized 91 
cell wall binding domain. The full-length 634 amino acid (aa) HydH5 and truncated 92 
version harboring just one lytic domain (and 6×His-tag) have been overproduced in E. 93 
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coli. The purified proteins are able to lyse viable S. aureus cells. HydH5 is highly 94 
thermostable since it showed antimicrobial activity after heat treatment (100ºC, 5 min) 95 
(39). 96 
 We have also characterized the endolysin LysH5 encoded by phiIPLA88 (33). 97 
LysH5 has three putative domains, a cysteine, histidine-dependent 98 
amidohydrolases/peptidase (CHAP) domain, an amidase-2 domain, and a C-terminal 99 
SH3b cell wall-binding (CWB) domain. LysH5 is able to inhibit the S. aureus growth in 100 
milk (33) and showed a synergistic antimicrobial effect with the bacteriocin nisin (13).  101 
 In order to enhance the antimicrobial activity of HydH5, in this work we have 102 
fused HydH5 to both full length and truncated fragments of lysostaphin, a staphylolytic 103 
bacteriocin produced by Staphylococcus simulans. Initially, a chimeric protein made up 104 
of complete proteins fused in a head to tail configuration was created. Similarly, both 105 
the complete HydH5 protein and just the HydH5 CHAP domain were fused to the SH3b 106 
CWB domain of lysostaphin in two separate constructs. The enzybiotic activity of all 107 
these constructs towards live S. aureus and numerous non-staphylococcal bacteria was 108 
assessed. Finally, we have also evaluated possible synergistic effects between HydH5 109 
and the endolysin LysH5, a PG hydrolase with different putative cleavage sites, with the 110 
purpose to explore new enzybiotic-based strategies to fight S. aureus infections.  111 
 112 
MATERIAL AND METHODS 113 
 114 
Bacterial strains and culture conditions. Vector constructs were performed in E. coli 115 
DH5α cells (Invitrogen, Carlsbad, CA) and induced in E. coli BL21(DE3) (EMD 116 
Biosciences, San Diego, CA). Bacterial strains used to determine the lytic spectrum of 117 
our constructs are listed in Table 1. S. aureus Sa9 was used as the indicator strain for 118 
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lytic activity (33). The S. aureus bovine isolates were from in-house stocks (IPLA-119 
CSIC), the S. aureus clinical isolates by Dr. Suárez (University of Oviedo, Spain), the S. 120 
epidermidis by Dr. Delgado (IPLA-CSIC) and the S. aureus MRSA strain N315 by 121 
Prof. Gabi Bierbaum (University of Bonn, Germany). All Staphylococcus strains were 122 
grown in TSB broth (Tryptic Soy Broth, DIFCO, Franklin Lakes, NJ) at 37ºC with 123 
shaking or in TSB plates containing 2% (w/v) bacteriological agar (TSA). Bacillus, 124 
Streptococcus, Listeria and Enterococcus strains were grown in 2 × YT at 37ºC with 125 
shaking. Clostridium strain was grown in BHI (Brain Heart Infusion, Scharlau, 126 
Barcelona, Spain) at 30ºC under static conditions and anaerobiosis (Anaerocult A, 127 
Merck, Darmstadt, Germany). Lactococcus strain was grown in M17 (Scharlau, 128 
Barcelona, Spain) at 30ºC and static. Leuconostoc and Lactobacillus strains were grown 129 
in MRS (Scharlau, Barcelona, Spain) at 30ºC and static. 130 
 131 
Plasmid constructs and DNA manipulation. Bacteriophage vB_SauS-phiIPLA88 132 
gene orf58 encoding HydH5 (Acc. Number ACJ64586) was codon-optimized (orf58-133 
opt) based on the E. coli codon usage (23) and commercially synthesized (Genescript, 134 
Piscataway, NJ, USA). Then orf58-opt was synthesized with a 5’ NdeI and a 3’ XhoI 135 
restriction enzyme sites and the resultant fragment was subcloned between the NdeI and 136 
XhoI sites in the multi cloning site of the inducible expression vector pET21a (EMD 137 
Biosciences, San Diego, CA) which introduces a C-terminal 6xHis-tag. All 138 
constructions in this work were created in this vector and thus have two additional aa 139 
residues introduced at the C-terminus corresponding to XhoI site (Leu-Glu) followed by 140 
the 6×His-tag (Fig. 1). Truncated versions of HydH5 were constructed via PCR 141 
amplification by introducing cloning sites with the PCR primers (Table 2).  142 
 143 
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Protein purification. Protein purification was performed as previously described (8) 144 
with the following modifications: Exponential growing cultures induced by IPTG (1 145 
mM, final concentration) were incubated at 10ºC for 20 h. Then 500 ml pellets were 146 
sonicated for 5 min using an automatic pulsing sonicator (Bronson Sonifier; Bronson 147 
Sonic Power Co., Danbury, CT, USA). Protein purification was carried out by NiNTA 148 
nickel column chromatography (Qiagen, Valencia, CA). Wash and elution profiles were 149 
empirically determined to be 20 ml of 10 mM imidazole, 40 ml of 20 mM imidazole 150 
and elution with 1 ml of 250 mM imidazole in phosphate buffered saline (50 mM 151 
NaH2PO4, 300 mM NaCl, pH 8.0) with 30% glycerol to prevent precipitation of the 152 
purified protein. Then all samples were converted to HydH5 activity buffer (HEPES 50 153 
mM, NDSB (Non-Detergent Sulfobetaine)-201 0.5 M, CaCl2 0.25 mM, MnCl2 0.25 154 
mM, MgCl2 0.25 mM, TCEP (Tris(2-carboxyethyl)phosphine) 1 mM, NaCl 24 mM, 155 
KCl 1 mM pH 7.5) (39) containing 30% glycerol using pre-equilibrated Zeba Desalting 156 
Columns (Thermo Fisher Scientific, Rockford, IL, USA). 157 
 158 
SDS-PAGE and zymogram analysis. Purity of HydH5 constructs were evaluated in a 159 
15% (v/w) SDS-PAGE in Tris-Glycine buffer at 150 V for 1.5 h using Criterion Precast 160 
gels (Bio-Rad, Inc., Hercules, CA). Zymogram assays were performed as previously 161 
described (39). SDS gels were stained via conventional Coomassie staining and 162 
zymograms were soaked for 30 min in distilled water to remove SDS and then 163 
incubated at room temperature in water for 15 min to detect areas of clearing in the 164 
turbid gel where a lytic protein is localized. 165 
 166 
Quantification of lytic activity. Turbidity reduction assay was performed against live 167 
S. aureus Sa9 cells prepared as previously described (8, 3). Specific activity of the 168 
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proteins was expressed as ΔOD600nm min-1μM-1. Plate lysis was performed as previously 169 
described (8). Serial 1:2 dilutions (in a range of 4 µM to 0.06) of each construct in 170 
HydH5 activity buffer were obtained. Then, drops (10 µl) of these dilutions were 171 
spotted onto a freshly plated, air-dried lawn of S. aureus Sa9, S. aureus MRSA N315 or 172 
the strains in Table 1 that were grown to an OD600nm= 0.5.  173 
 174 
Synergy. Checkerboard minimum lytic concentration (MLC) tests were performed 175 
between LysH5 (33) and HydH5 and between LysH5 (Acc. Number EU573240) and 176 
HydH5-derived constructs using live S. aureus Sa9 cells suspensions in HydH5 activity 177 
buffer at a final OD600nm of ~0.8. MLCs are defined as the lowest concentration of 178 
enzyme required to drop the turbidity of S. aureus Sa9 strain from 0.9 to 0.1 OD600nm 179 
after 15 minutes of incubation at 37°C (13). Ranges of enzyme concentrations were: 180 
LysH5 (2.5 μg/ml to 0.04 μg/ml); HydH5 (56.7 μg/ml to 0.06 μg/ml), HydH5Lyso (25.1 181 
μg/ml to 0.02 μg/ml), HydH5SH3b (13.5 μg/ml to 0.01 μg/ml) and CHAPSH3b (17.34 182 
μg/ml to 0.03 μg/ml). The fractional inhibitory concentration (FIC) was calculated as 183 
the minimum lytic concentration (MLC) of the antimicrobial in combination divided by 184 
the MLC of the antimicrobial acting alone. Strong synergy exists if the sum of the two 185 
FICs [ΣFIC=FICA+FICB] is <0.5 (15). All experiments were performed in duplicate. 186 
 187 
RESULTS 188 
 189 
Fusion to lysostaphin sequences increases the HydH5 and CHAP lytic activity. To 190 
determine whether both the CHAP and LYZ2 as single domains showed increased lytic 191 
activity toward S. aureus Sa9 over those previously obtained (39), four deletion 192 
constructs were generated. A schematic representation of all constructs is presented in 193 
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Fig. 1. In order to ensure proper folding, each construct contained a single lytic domain 194 
with an additional 7 or 17 aa flanking the catalytic domain (CHAP156, CHAP166, 195 
LYZ161 and LYZ171) in order to help maintain the normal protein environment of the 196 
domain and thus enhance correct folding. In addition, due to the lack of a known CWB 197 
domain in HydH5, we proceeded to determine whether the addition of a CWB domain 198 
might increase the lytic activity of HydH5 and CHAP. Three different fusion proteins 199 
were created between lysostaphin and HydH5 (Fig. 1). Initially, the lysostaphin binding 200 
domain SH3b was fused to the full-length HydH5 protein, resulting in a protein with 201 
two catalytic domains and one CWB domain (HydH5SH3b). A second construct was 202 
obtained by fusion of the CHAP156 domain to the lysostaphin SH3b domain 203 
(CHAPSH3b). Finally, the full-length lysostaphin and HydH5 were fused in order to 204 
obtain a protein with three catalytic domains and a CWB (HydH5Lyso). All the fusion 205 
proteins could be detected and purified with the exception of LYZ161 and LYZ171 206 
whose products could not be detected after nickel column purification of the E. coli 207 
cultures. 208 
 Due to reports that PG hydrolase lytic activity is not always quantitatively 209 
comparable between multiple assays (22), the lytic activities of the other proteins 210 
(HydH5, CHAP156, CHAP166, HydH5SH3b, CHAPSH3b and HydH5Lyso) were 211 
determined in three antimicrobial assays: zymogram, plate lysis and turbidity reduction 212 
assays. As shown in Fig. 2A, all nickel column purified proteins were >95% pure and  213 
created a single zone of clearing in the zymogram, consistent with the predicted 214 
molecular mass and positions of the purified proteins in the SDS-PAGE. The activity of 215 
both truncated constructs (CHAP156 and CHAP166) turned out to be the same 216 
regardless of the length of the lytic domain protein fragment. Therefore, only the results 217 
obtained with CHAP156 are presented.  218 
 10
 In the plate lysis assay (Fig. 2B) the full-length HydH5 showed clearing of S. 219 
aureus at ≥ 2 μM concentration while the CHAP domain required higher concentrations 220 
(≥ 16 μM). All the fusion proteins showed significantly greater activity than the parental 221 
protein HydH5, even against a methicillin-resistant S. aureus MRSA N315 strain. 222 
HydH5 has clear staphylolytic activity at 4 µM while the fusion proteins showed lytic 223 
activity at much lower concentrations (1 µM). Fusion of SH3b to the CHAP domain 224 
also increased CHAP activity against both, S. aureus Sa9 and S. aureus MRSA N315 225 
strains, for 64-fold (Fig. 2B).  226 
 Proteins were also tested by turbidity reduction assay (Fig. 2C). This assay was 227 
performed using 1 µM of purified proteins. The full-length recombinant HydH5, 228 
synthesized from the E. coli codon optimized version of orf58opt, showed a lytic 229 
activity in this assay in contrast to that previously observed in HydH5 from the standard 230 
orf58 (39). The recombinant HydH5 was able to lyse live S. aureus Sa9 cells and had a 231 
specific activity of 0.033 ± 0.009 ∆OD600nm min-1µM-1 (Fig. 2C). Similar results were 232 
obtained for the CHAP domain with ~ 1.4-fold reduction in specific activity (0.023 ± 233 
0.001 ∆OD600nm min-1µM-1) observed when compared to full-length HydH5 activity. 234 
Fusion proteins, HydH5Lyso and HydH5SH3b, showed a 2.5- and 1.7-fold higher 235 
specific activity than the parental protein HydH5, respectively. CHAPSH3b showed an 236 
activity 4.8-fold greater than CHAP domain. The specific activity of CHAPSH3b was 237 
calculated to be 0.109 ± 0.023 ∆OD600nm min-1µM-1 the highest lytic activity obtained 238 
from HydH5 fusions. Therefore, C-terminal lysostaphin fusions conferred an enhanced 239 
staphylolytic activity to HydH5 and its catalytic domain CHAP.  240 
 241 
The lytic activity of HydH5 and its derivative fusions is specific for staphylococci. 242 
In order to determine the specificity of the HydH5 and its derivative fusions, different 243 
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bacterial cells suspensions were exposed to 2 µM protein solutions by the plate lysis 244 
assay. We found that 10 µl of 2 µM HydH5-derived fusions, HydH5SH3b and 245 
CHAPSH3b, were able to lyse all S. aureus and S. epidermidis strains (14 tested; Table 246 
1). In contrast, 10 µl of 2 µM HydH5Lyso was able to lyse all the S. aureus strains and 247 
only 2 out of 4 S. epidermidis strains. S. epidermidis lysis could be achieved at 4 µM 248 
(data not shown). A variety of bacteria representing several genera [Bacillus, 249 
Streptococcus, Clostridium, Lactococcus, Leuconostoc, Lactobacillus, Listeria and 250 
Enterococcus] were not affected by any of the staphylolytic proteins. It was observed 251 
that the degree of lytic activity on S. epidermidis strains was generally lower than that 252 
observed for S. aureus strains. Moreover, the spectrum of species lysed was not 253 
consistent for all proteins despite a similar origin of the domains. HydH5 and 254 
HydH5Lyso were less active in this assay with CHAPSH3 showing higher lytic activity 255 
against S. epidermidis strains (Table 1). In addition to the lytic activity differences 256 
between species, host strain origin may also play a role in determining the spectrum of 257 
susceptible species. There is a trend for the HydH5 derived enzymes to show greater 258 
lysis against bovine-associated staphylococci than clinical isolates. This is consistent 259 
with the fact that phiIPLA88 was isolated from a dairy environment. The HydH5 260 
parental enzyme is active on 4/5 of the bovine isolates and only active on 1/5 of the 261 
human S. aureus isolates. The trend is diminished but still apparent with the fusion 262 
enzymes (HydH5Lyso and HydH5SH3b) (Table 1).  263 
 264 
HydH5 and its fusions act synergistically with LysH5 against S. aureus. To 265 
determine the interaction of HydH5 and its derivative fusions with the endolysin LysH5 266 
a standard checkerboard dilution assay was performed using live S. aureus Sa9 cells in 267 
HydH5 activity buffer. Initially, we determined the MLC of each protein: HydH5 (56.7 268 
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μg/ml), HydH5Lyso (12.5 μg/ml), HydH5SH3b (13.5 μg/ml), CHAPSH3b (8.7 μg/ml) 269 
and LysH5 (2.5 µg/ml). When HydH5 or its derived fusions were combined with 270 
LysH5, a synergistic effect was observed in all combinations. Representative graphs of 271 
the synergistic interaction between LysH5 and HydH5 and between LysH5 and each 272 
HydH5-lysostaphin construct are shown in Fig. 3. From the checkerboard test, the 273 
average ΣFIC values for the four protein combinations were calculated (Fig. 3). All 274 
these values are indicative of strong synergistic interaction and mixtures of these 275 
enzymes are more inhibitory for S. aureus growth. 276 
 277 
DISCUSSION 278 
 279 
 With the goal to increase the antimicrobial activity of HydH5 and determine the 280 
spectrum of species susceptible to lysis with the lytic domains of this enzyme, we 281 
performed deletion analysis and created multiple lytic domain fusion proteins with the 282 
most active HydH5 lytic domains. Through deletion analysis we had identified in 283 
HydH5 the protein domains that are essential for its activity and showed that both 284 
CHAP and LYZ2 domains possess lytic activity against S. aureus cells (39). Several 285 
reports have shown that endolysins can be truncated and some individual catalytic 286 
domains retain lytic activity with some of them showing higher specific activity than the 287 
full length protein (4, 17, 7, 2). However, as was previously shown some endolysin 288 
catalytic domains are almost inactive, such as the glycosidase domains from lambdaSa2 289 
prophage endolysin (8), or the B30 endolysin (7) and the amidase domain from LysK 290 
(2). Although our results might result from protein instability or aberrant protein 291 
folding, the HydH5 CHAP domain construct has approximately 1.4-fold lower specific 292 
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activity compared to the activity of the full-length HydH5, suggesting that LYZ2 293 
domain might also contributes to the full-length protein’s activity.  294 
  We and others have shown previously that virion-associated PG hydrolases 295 
lacking a defined CWB domain can also bind to the cell surface (38, 39). Known CWB 296 
domains have been shown for some PG hydrolases to be necessary for accurate cell wall 297 
recognition and subsequent lytic activity, such as, lysostaphin (1), ALE-1 (27), L. 298 
monocytogenes endolysins Ply118 and Ply500 (25) and S. pneumoniae CPL-1 (36). 299 
However, there are numerous reports of C-terminally deleted lysin constructs with 300 
deleted CWB domains where the N-terminal lytic domain maintains its activity in the 301 
absence of its CWB domain (4, 40, 17, 7, 2). Thus a defined CWB domain is not a 302 
necessity for full lytic activity, and this binding does not rule out the possibility that the 303 
inter-lytic domain region might harbor a heretofore unidentified CWB domain as 304 
suggested previously for the B30 endolysin (7). 305 
 Our hypothesis to justify the addition of a CWB domain considers the fact that a 306 
phage structural protein, HydH5, is likely brought into close proximity of the cell wall 307 
and the PG substrate by the intact virion. However, when considering HydH5 as a 308 
soluble single protein antimicrobial, the scenario is quite different and the addition of a 309 
CWB domain might improve its lytic activity. In the HydH5SH3b construct, the 310 
lysostaphin SH3b domain was fused to full-length HydH5 increasing the lytic activity 311 
1.7-fold, suggesting that the CWB domain helped the lytic domain degrade the PG 312 
substrate. A similar result was obtained when the native Cpl-7 cell wall binding 313 
domains of the streptococcal LambdaSa2 endolysin were replaced by the staphylococcal 314 
SH3b domain from lysostaphin or LysK resulting in a 5-fold increase in staphylolytic 315 
activity of the LambdaSa2 CHAP endopeptidase domain (3). In the HydH5 CHAPSH3b 316 
construct, the lysostaphin SH3b domain was fused to the CHAP domain resulting in a 317 
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4.8-fold increase in the lytic activity of the CHAP alone construct (CHAP) and a 3.3-318 
fold increase compared to full length HydH5. This result indicates the importance of the 319 
SH3b CWB domain in recognizing the bacteria cell wall, taking into account that only 320 
one catalytic domain (CHAP) fused to the SH3b domain was sufficient to obtain the 321 
highest specific activity of the various constructs. 322 
 Moreover, addition of the full length lysostaphin to HydH5 (HydH5Lyso) also 323 
achieved greater activity levels than the parental protein (HydH5). This result further 324 
indicates the modular nature of these protein domains and supports our hypothesis that 325 
the addition of new catalytic domains to HydH5 can improve its lytic activity. The three 326 
different catalytic domains are believed to each attack a different PG bond. The 327 
presence of multiple unique domains theoretically decreases the likelihood of bacterial 328 
resistance development (10). The increased activity also suggests that each domain is 329 
modular, as expected (12), and although the activity of the final construct does not 330 
achieve the sum of the parental lytic activities, each domain likely achieves a near-331 
native conformation.  332 
 HydH5 and its derivative fusions were assessed for their ability to lyse a range 333 
of staphylococcal and non-staphylococcal strains. No previous data have been reported 334 
regarding the lytic spectrum of S. aureus virion-associated PG hydrolases. All proteins 335 
were active against staphylococcal strains but no other genus was lysed at detectable 336 
levels. Our results indicate a similar lytic spectrum for both HydH5 and its derivative 337 
fusions. These results are in agreement with S. aureus endolysins described to date that 338 
demonstrate a lytic spectrum limited to staphylococci. However, a different level of the 339 
lytic activity was observed for each species/strain. In general, S. aureus strains were 340 
more sensitive to lysis than S. epidermidis strains. Within the S. aureus strains, we 341 
observed a trend wherein bovine strains were more sensitive than clinical strains. This 342 
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could be due to the shared origin of these strains and the phage from which HydH5 343 
originated, both share a source from a dairy environment. A similar result was 344 
previously observed for endolysin LysH5 (33). Similarly, lysostaphin is known to have 345 
a reduced activity against S. epidermidis compared to S. aureus (44). Although we do 346 
not yet have direct biochemical proof that all three lytic domains are functional in the 347 
HydH5Lyso construct, the reduced activity against S. epidermidis compared to S. 348 
aureus, and the increased activity against human isolates while maintaining the high 349 
activity against bovine strains is consistent with the combined lytic range of both 350 
HydH5 and lysostaphin and suggests that both protein fragments are functional in this 351 
fusion construct.  352 
 Synergistic interactions between antimicrobial compounds have the potential to 353 
be exploited in order to increase effectiveness against the target bacteria, thereby 354 
reducing the dose required of each antimicrobial compound while simultaneously 355 
decreasing the likelihood of antimicrobial-resistance development. The combination of 356 
the two lytic bacteriophage enzymes HydH5 and LysH5 appears to have synergistic 357 
activity on S. aureus Sa9 strain. Also HydH5 derived fusions showed this positive 358 
interaction. The basis of synergy between PG hydrolases might be explained by the 359 
hydrolytic activity of one enzyme loosening the PG structure, thus facilitating better 360 
access of the second enzyme to its target, or potentially by creating a better substrate for 361 
the second “weaker” domain. It is encouraging that the strongest in vitro synergy was 362 
observed between LysH5 and HydH5Lyso, suggesting that this combination might be 363 
protective in vivo. However, in the absence of biochemical data to indicate which 364 
domains are active in the fusion and the parental LysH5, we are at a loss to fully 365 
identify those domains that are responsible for the observed antimicrobial synergy. 366 
However, these results are in agreement with previous studies indicating synergy 367 
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between Pal and Cpl-1 lysins against S. pneumoniae (24), and the synergy between 368 
endolysin LysK and the bacteriocin lysostaphin against S. aureus. A 33% reduction in 369 
LysK concentration was obtained in the presence of lysostaphin (2). Another 370 
bacteriocin, nisin, enhanced the antimicrobial activity of LysH5 8-fold on S. aureus cell 371 
suspensions (13). Comparable results were obtained by combination with antibiotics 372 
(28, 5). 373 
 In summary, we report the development of novel chimeric PG hydrolases with 374 
improved lytic activity against S. aureus and S. epidermidis, including the MRSA N315 375 
strain. The effectiveness of HydH5 and its derivative fusions when used in combination 376 
with LysH5, another dairy derived anti-staphylococcal protein were remarkable. We 377 
expect that these constructs will provide new weapons to combat multidrug-resistant S. 378 
aureus infections in both dairy and clinical environments.  379 
 380 
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TABLES 546 
Table 1. Lytic spectrum of the peptidoglycan hydrolase HydH5, its derivative fusions, 547 
and lysosthaphin. Bacterial strains were exposed to 2 µM of each protein. Strong lytic 548 
halo (+++), medium (++), weak (+) and no halo (-) was indicated. Nd, not determined.   549 
 PROTEIN 
STRAIN HydH5 HydH5Lyso HydH5SH3b CHAPSH3b Lysostaphin
S. aureus     
Bovine strains     
Sa9 + ++ +++ +++ +++ 
Sa6 - +++ +++ +++ +++ 
Sa11 + +++ +++ +++ +++ 
AFG1 + ++ +++ +++ +++
AC9 + + +++ +++ +++ 
Human strains      
N315 - ++ +++ +++ +++ 
96 - + ++ +++ +++ 
143 - + + ++ +++ 
445 - ++ +++ +++ +++ 
c4 + ++ +++ +++ +++ 
S. epidermidis     
B - ++ + +++ ++ 
C213 - ++ +++ +++ ++ 
Z2LDC17 + + ++ +++ - 
DH3LIK - ++ + +++ ++ 
Bacillus cereus ATCC 9139 - - - - nd 
Streptococcus pneumoniae R6 - - - - nd 
Clostridium tyrobutiricum CECT 4012 - - - - nd 
Lactococcus lactis IPLA 947 - - - - nd 
Leuconostoc lactis IPLA 567 - - - - nd 
Lactobacillus citreum IPLA 979 - - - - nd 
Listeria monocytogenes ScottA - - - - nd 
Enterococcus faecalis CNRZ 1352 - - - - nd 
 550 
 551 
 552 
 553 
 554 
 555 
 556 
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Table 2. Primers used in this study. The location of the restriction enzyme site 557 
(underlined) relative to the nearest aa residue in the protein is indicated.  558 
 559 
Protein Primers Restriction site aa 
CHAP156 
domain 
CHAP156R: 5’- CTGACTGCTCGAGTTTGTCCGGGTG- 3’ 
pET21aBglII-F: 5’- CGTAGAGGATCGAGATCTCGATC- 3’ 
XhoI 156 
CHAP166 
domain 
CHAP166R: 5’ -ATCGACTGCTCGAGTTTCGGCACCGG- 3’ 
pET21aBglII-F: 5’- CGTAGAGGATCGAGATCTCGATC- 3’ 
XhoI 166 
LYZ161 
domain 
LYZ161F: 5’- ACTGACTGCATATGGTTAGCGTCTCC- 3’ 
pET21aStyI-R: 5’- CGTTTAGAGGCCCCAAGGGGTTATG- 3’ 
NdeI 475 
LYZ171 
domain 
LYZ171F: 5’ –ACTGACTGCATATGCAAATGCTGAAC- 3’ 
pET21aStyI-R: 5’- CGTTTAGAGGCCCCAAGGGGTTATG- 3’ 
NdeI 465 
Lysostaphin Full Lyso SalI-F (5’- 
ATCATCGTCGACGCTGCAACACATGAACATTCAGCAC- 3’ 
pET21aStyI-R: 5’- CGTTTAGAGGCCCCAAGGGGTTATG- 3’ 
SalI  
SH3b 
domain 
Lyso SalI144- F (5′-GGAAAAGCAGTCGACACAGTAACTCC-3′ 
pET21aStyI-R: 5’- CGTTTAGAGGCCCCAAGGGGTTATG- 3’ 
SalI  
 560 
561 
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FIGURES 562 
 563 
Figure 1. Schematic representation of HydH5 deletion and fusion constructs. The 564 
numbers indicate the initial and final aa in the domains as determined by Pfam domain 565 
database. Grey box: CHAP domain; horizontal stripes: LYZ2 domain; diagonal stripes 566 
= SH3b domain; large black box: endopeptidase domain; small black box: 6×His-tag. 567 
 568 
Figure 2.  Antimicrobial activity of HydH5, deletion and fusion constructs. A) SDS-569 
PAGE and zymogram analysis of 5 µg nickel affinity purified proteins. Lane M: 570 
Standard molecular mass marker in kDa (Prestained SDS-PAGE Standards, broad 571 
range, BioRad Laboratories); lane 1, CHAP (19.6 kDa); 2, HydH5 (73.6 kDa); 3, 572 
HydH5SH3b (85.1 kDa); 4, HydH5Lyso (100.8 kDa); 5, CHAPSH3b (30.4 kDa); 6, 573 
Lysostaphin (28.1 kDa).  B) Plate lysis assay of HydH5 and derived proteins using mid-574 
log phase growing cells of S. aureus Sa9 and MRSA strain N315. C) Turbidity 575 
reduction assay results using 1 µM of each protein. Specific activity is expressed as 576 
ΔOD600nm min-1µM-1.Error bars are the means ± standard deviations of three 577 
independent assays.  578 
  579 
Figure 3. Synergistic effect in checkerboard assay between endolysin LysH5 and 580 
HydH5 fusion constructs. Minimum Lytic Concentration (MLC) of each protein in the 581 
presence of subinhibitory concentrations of endolysin LysH5 is indicated. A (HydH5, 582 
56.7 μg/ml to 0.06 μg/ml, ΣFIC 0.065 ± 0.001), B (HydH5SH3b, 13.5 μg/ml to 0.01 583 
μg/ml, ΣFIC 0.130 ± 0.000), C (HydH5Lyso, 25.1 μg/ml to 0.02 μg/ml, ΣFIC 0.049 ± 584 
0.023), and D (CHAPSH3b, 17.34 μg/ml to 0.03 μg/ml, ΣFIC 0.063 ± 0.022).  585 
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